A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.

Takahashi S, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Fukuda N, Sasaki T, Suzuki T, Ikezawa H, Dutcus CE, Tahara M

Open source

DOI: 10.2217/fon-2018-0557
Published: 2019 Mar
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2217/fon-2018-0557,
  title = {A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.},
  author = {Takahashi S and Kiyota N and Yamazaki T and Chayahara N and Nakano K and Inagaki L and Toda K and Enokida T and Minami H and Imamura Y and Fukuda N and Sasaki T and Suzuki T and Ikezawa H and Dutcus CE and Tahara M},
  year = {2019},
  journal = {Future oncology (London, England)},
  doi = {10.2217/fon-2018-0557},
  url = {https://doi.org/10.2217/fon-2018-0557}
}

RIS

TY  - JOUR
TI  - A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
AU  - Takahashi S
AU  - Kiyota N
AU  - Yamazaki T
AU  - Chayahara N
AU  - Nakano K
AU  - Inagaki L
AU  - Toda K
AU  - Enokida T
AU  - Minami H
AU  - Imamura Y
AU  - Fukuda N
AU  - Sasaki T
AU  - Suzuki T
AU  - Ikezawa H
AU  - Dutcus CE
AU  - Tahara M
PY  - 2019
JO  - Future oncology (London, England)
DO  - 10.2217/fon-2018-0557
UR  - https://doi.org/10.2217/fon-2018-0557
ER  -

APA

S, T., N, K., T, Y., N, C., K, N., L, I., K, T., T, E., H, M., Y, I., N, F., T, S., T, S., H, I., CE, D., & M, T. (2019). A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.. Future oncology (London, England). https://doi.org/10.2217/fon-2018-0557

Source records

pubmed · retrieved 2026-09-26T18:42:03.310Z